EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Persistent immune-related toxicity in cancer survivors at least one year after pembrolizumab discontinuation

Silvia del-Barrio-Buesa, María Amparo Lucena-Campillo, Vicente Escudero-Vilaplana, Eva González-Haba-Peña, Cristina Villanueva-Bueno, José Luis Revuelta-Herrero, María del Pilar Montero-Antón, María Martín-Bartolomé, Ana Herranz-Alonso, María Sanjurjo-Sáez

Farmacia Hospitalaria · 2026-11

DOI: 10.1016/j.farma.2026.09.012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Farmacia Hospitalaria, 2026-11. Verfasst von Silvia del-Barrio-Buesa und 9 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Graphical abstract summarizing the main findings on persistent immune-related adverse events after pembrolizumab discontinuation.

Zitieren

APA

del-Barrio-Buesa, S., Lucena-Campillo, M. A., Escudero-Vilaplana, V., González-Haba-Peña, E., Villanueva-Bueno, C., Revuelta-Herrero, J. L., Montero-Antón, M. D. P., Martín-Bartolomé, M., Herranz-Alonso, A., & Sanjurjo-Sáez, M. (2026). Persistent immune-related toxicity in cancer survivors at least one year after pembrolizumab discontinuation. Farmacia Hospitalaria. https://doi.org/10.1016/j.farma.2026.09.012

Vancouver

del-Barrio-Buesa S, Lucena-Campillo MA, Escudero-Vilaplana V, González-Haba-Peña E, Villanueva-Bueno C, Revuelta-Herrero JL, et al. Persistent immune-related toxicity in cancer survivors at least one year after pembrolizumab discontinuation. Farmacia Hospitalaria. 2026. doi:10.1016/j.farma.2026.09.012

BibTeX
@article{delBarrioBuesa2026,
  author = {del-Barrio-Buesa, Silvia and Lucena-Campillo, María Amparo and Escudero-Vilaplana, Vicente and González-Haba-Peña, Eva and Villanueva-Bueno, Cristina and Revuelta-Herrero, José Luis and Montero-Antón, María del Pilar and Martín-Bartolomé, María and Herranz-Alonso, Ana and Sanjurjo-Sáez, María},
  title = {Persistent immune-related toxicity in cancer survivors at least one year after pembrolizumab discontinuation},
  journal = {Farmacia Hospitalaria},
  year = {2026},
  doi = {10.1016/j.farma.2026.09.012}
}
Kostenlos starten →